REG - Creo Medical Group - Kamaptive Licence and Royalty Agreement with CMR

Creo MedicalAnnouncement

24/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221024:nRSX7875Da&default-theme=true

RNS Number : 7875D  Creo Medical Group PLC  24 October 2022

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Kamaptive Licence and Royalty Agreement with CMR Surgical

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that it has signed a
non-exclusive Intellectual Property Licence and a Royalty Agreement with CMR
Surgical Limited, the global surgical robotics business, to integrate certain
aspects of Creo's technology with the Versius® Surgical Robotic System,
through Creo's "Powered by Kamaptive" licensing programme. Licensing terms and
commercial royalties have been agreed but will remain undisclosed.

 

CMR's next-generation surgical robot, Versius®, is a significant new entrant
into the robotic surgery space and is being used to perform both routine and
complex laparoscopic procedures worldwide across a range of specialties
including gynaecology, colorectal surgery, thoracic surgery, general surgery
and urology.

 

Through Creo's Kamaptive licensing programme, strategic partners are being
carefully selected with whom Creo can licence and develop its technology for
use in adjacent and complementary markets. The Agreements are the latest
licensing deal under Creo's Kamaptive licensing programme.

Craig Gulliford, Chief Executive Officer of Creo, commented: "We are delighted
to announce our second robotics partnership through our Kamaptive programme
with CMR Surgical. Versius® has been used for a wide range of laparoscopic
procedures worldwide, and we look forward to collaborating with CMR to
integrate Creo's ground-breaking minimally invasive technology with the
Versius® system, driven by a shared goal to improve outcomes for even more
patients. Exploring the use of our technology in the fast-growing robotic
surgery space with another prestigious partner provides further validation of
our technology and its versatility."

 

About Kamaptive Technology

Creo has developed multi-modal adaptive technology to optimise surgical
capability and patient outcomes under its "Powered by Kamaptive" brand.
Kamaptive is a seamless, intuitive integration of energy sources, optimised to
dynamically adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled surgical
solutions and lies at the heart of Creo's CROMA Advance Energy platform and
associated electrosurgical medical device technology.

 

This announcement contains inside information.

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

About CMR Surgical Limited

CMR Surgical (CMR) is a global medical devices company dedicated to
transforming surgery with Versius(®), a next-generation surgical robot.

 

Headquartered in Cambridge, United Kingdom, CMR is committed to working with
surgeons, surgical teams and hospital partners, to provide an optimal tool to
make robotic minimal access surgery universally accessible and affordable.
With Versius, we are on a mission to redefine the surgical robotics market
with practical, innovative technology and data that can improve surgical care.

 

Founded in 2014, CMR Surgical is private limited company backed by an
international shareholder base.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBLBDGGSDDGDD